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OUTCOME ASSESSMENT OF INTERMITTENT
CLAUDICATION IN CLINICAL PRACTICE (SEE
ALSO A 2.2, INTERMITTENT CLAUDICATION,
P S4)
A detailed assessment of outcomes necessary for clini-
cal trials or published studies is discussed in B6,
Clinical Trial Issues (p 5108). IC is an indicator of not
only blood flow-limiting lesions within the arterial
tree of the lower extremity but also clinically signifi-
cant systemic atherosclerosis. As such, IC exerts a
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global impact on the patient. Patients so afflicted expe-
rience broad limitations in their level of daily function-
ing that extend beyond the ambulatory disability.
Using a variety of quality-of-life assessment instru-
ments, such as the SF-36 and the Nottingham Health
Profile, investigators have documented increased bod-
ily pain and decreased physical, emotional, social func-
tions, and worse perceived health as well as a variety
of other disturbances in patients with claudication
compared with age-matched controls. 1•2.3,4,5
Appropriate therapeutic goals for the treatment of
the claudicant must address both the specific lower-
extremity disability and the systemic impact of the
disease. Ideally, treatment will result in an improve-
ment in both the vascular status of the lower extremi-
ty and the patient's general health status, indicated by
at least four attributes on the SF-36 or RAND-36, and
level of functioning, indicated by at least two attrib-
utes on the WIQ. The complete assessment of the out-
comes of treatment of the claudicant, therefore,
requires the use of both clinical and patient-based
parameters. It is impossible to define "relevant"
improvement.
Recommendation 19: Success of treatment for inter-
mittent claudication
Ideally, success of treatment for intermittent claudi-
cation should take into account an improvement in
the following:
• Objective outcome: relevant improvement in
walking distance as measured by a standardised
exercise test
• Symptomatic outcome: improvement on a
validated disease-specific health status
questionnaire
• General quality of life: improvement on a validat-
ed generic health status questionnaire
• Postrevascularisation: objective proof of patency
of any revascularised segment (ideally with
imaging)
B 3.1.1
Relationship Between Clinical and Quality-of-Life
Outcomes Parameters
Despite the performance of a complete clinical evalu-
ation, physicians cannot accurately assess the overall
impact of IC on the patient. PeW compared quality-of-
life assessments of 201 claudicants before their first
visit to their vascular surgeon with the surgeon's
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impression of the patient's symptoms and examina-
tion. The correlation between these two assessments
was poor.
Studies evaluating patients with IC by walking
distance, ABPI, and quality of life have also demon-
strated a poor or limited correlation between the clin-
ical parameters and quality-of-life index. Assessing
157 claudicant patients with treadmill walking dis-
tance, ABPI, and the EuroQol generic quality-of-life
survey, Chetter et al6 noted a poor correlation
between the clinical parameters of treadmill walking
distance and ABPI and the measured quality of life.
Barletta et aF evaluated treadmill performance and
the quality of life with the McMaster Health Index
Questionnaire in 251 patients and 89 age-matched
controls. These investigators documented a reduc-
tion in physical, emotional, and social function in
patients with IC compared with controls, but the
reduction in these quality-of-life parameters did not
correlate well with treadmill performance.
Similarly, the clinical outcome of treatment does
not directly correlate with quality-of-life outcomes.
An optimal interventional result represents a step
toward the achievement of an improved functional
status, but it is not indicative of an overall improve-
ment in the patient's quality of life. Currie et al8 stud-
ied 186 patients undergoing treatment for claudica-
tion by unsupervised exercise, angioplasty, or sur-
gery and documented that angioplasty and surgery
improved quality-of-life scores, but the improvement
did not correlate with changes in the ABPI. Gibbons
et al? found that the only independent predictor of
improved function and well-being in 156 patients
after infrainguinal revascularisation was the
patients' perception of their status at baseline: those
patients who functioned better before operation
reported improved function and well-being at
6 months.
Schneider et al!? evaluated the functional status
and well-being of 60 patients who had undergone
successful aortobifemoral bypass grafting at least 6
months earlier. They found that physical function,
role function, and perceived health were worse and
bodily pain greater than in those without sympto-
matic arterial occlusive disease, despite a patent
bypass. These findings indicate that clinical meas-
ures, such as ABPI, patency, and limb salvage, effec-
tively assess the physiological impact of vascular
intervention but do not adequately describe overall
patient benefit or adverse effect. This lack of correla-
tion underscores the need to use both clinical and
quality-of-life parameters to adequately determine
the impact of vascular disease and its treatment on
the claudicant (see Critical Issue 1, p S33).
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Critical Issue 5: Outcome measures of intermittent
claudication therapy in clinical practice
Several validated and established methods assess
outcome of claudication therapy in clinical trials
(eg, treadmill walking distance, functional status,
and quality-of-life questionnaires). Future studies
are needed to develop practical methods to assess
outcome measures of intermittent claudication ther-
apy that can be used in everyday clinical practice.
Clinicai Measurcs: Walkil/g Distance
Because the major clinical manifestation of IC is walk-
ing impairment, walking distance is the primary
objective parameter for the assessment of treatment.
This is best evaluated through the use of a standard-
ised exercise protocol. The general details regarding
the performance of a treadmill exercise test are pro-
vided in Basic Treatment (p S68). Either the distance to
the onset of claudication (initial claudication distance
[ICD]) or the absolute (maximal) claudication distance
(ACD) achieved on a treadmill at a constant speed and
percent incline can be used to evaluate the success of
treatment over time. The same value must be used for
each subsequent evaluation.
Walking distance may change in a manner inde-
pendent of the ABPI.1I·12 Therefore, though the ABPI is
of value in determining the severity of impairment of
arterial flow (see B 2.2.1, Routine Tests, p S54) and
patency of the revascularised and distal arterial seg-
ments within the lower extremity (see also A 3.2.9,
Patency, p S37), walking distance is the most appro-




The severity of PAD can be judged by classifying
patients' symptoms on a scale of six categories (see
Table 9, p S34). Three categories are pertinent to clau-
dication: category 1 indicates mild, category 2 moder-
ate, and 3 severe claudication. Symptomatic improve-
ment of claudication requires an upward shift of at
least one category on this scale. These three levels of
severity, of help to the clinician in planning therapy,
are based largely on walking ability. The Walking
Impairment Questionnaire assesses the cause and
degree of walking discomfort, the patient's estimate of
walking distance, walking speed, and stair-climbing
ability (see A 3.2.6, Disease-Specific Health Status
Questionnaires, p S34). This questionnaire provides a
simple measure of symptomatic improvement beyond
that indicated by treadmill testing. It is widely used
for evaluation of the claudicant, increasing its value as
an outcomes measure.
General quality of life
The SF-36 has been broadly applied to patients with IC
before and after intervention. Though scores do not
correlate directly with clinical parameters, such as
AI3PI or graft patency, they show the impact of treat-
ment on the patient. As with other generic health sta-
tus questionnaires, the SF-36scores may be affected by
patient ageP A younger patient, for example, may
experience a greater overall negative impact from
claudication than an older patient because of differing
needs for walking. Therefore, appropriate interpreta-
tion of scores may require stratification of the patient
sample by age. The timing of patient assessment
through use of a generic health status instrument is
also important, especially in the posttreatment period.
Because of the numerous comorbid conditions experi-
enced by those with IC, patients may show changes in
their health status scores despite continued patency of
the treated arterial segment. Using the SF-36, Currie et
al8 noted a significant improvement in physical func-
tion and pain scores shortly after either balloon angio-
plasty or surgical intervention in the c1audicant.
Pell and Lee13 found that improvements in these
scores on the SF-36 persisted at 6 months after treat-
ment but continued to deteriorate in those managed
without intervention in a review of 195 patients. At 1
year after balloon angiopIasty, Cook and Calland'!
documented with the EuroQol questionnaire a
decrease in perceived health scores despite main-
tained improvement in walking distance in 24 patients
with Ie. By 2 years after intervention with balloon
angioplasty, Whyman et aP5reported no differences in
quality-of-life scores between two groups of patients
with IC-those treated by angioplasty and those treat-
ed medically. These data confirm the global impact of
claudication on the patient and underscore the sys-
temic nature of the disease. The assessment of the suc-
cess of an intervention performed for the treatment of
IC by a generic health status questionnaire requires
documentation of the date of intervention.
Postreoascularisation
The clinical result of any intervention for IC should be
documented through postprocedural ABPI and imag-
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ing studies that detail the area of intervention. A
reduction in ABPI should be correlated with the
images of the treated segment to determine whether a
reduction in index has been caused by problems with-
in the treated segment or by progressive disease prox-
imal or distal to the treated segment.
Recommendation 20: Reporting intermittent claudi-
cation outcomes separately from critical limb
ischaemia
Results of treatment in patients with intermittent
claudication should be analysed separately from
those of patients with critical limb ischaemia.
83.1.3
Impact of Outcomes Assessment on Management of
Intermittent Claudication
Only through an understanding of the specific and
overall effects of vascular disease on the patient can
physicians develop appropriate therapeutic plans.
Management guidelines for treatment and definitions
of success of treatment should consider all types of
outcomes. For example, a patient with mild claudica-
tion according to the walking distance categories
should be considered for treatment if his or her quali-
ty of life is severely impacted by the disease as meas-
ured by the health-related quality-of-life measures.
Conversely, a patient with severe claudication would
not require treatment if his or her quality of life is not
affected by the disease. Success of an intervention is
defined as improvement of at least one category and
should be considered for each of the outcomes meas-
ures. If more than one attribute is measured for a par-
ticular outcome measure, improvement should be
defined as an upward shift of at least one category on
at least half of the attributes, for example, at least two
attributes on the WIQ and at least four attributes on
the 5F-36/RAND-36 (see Critical Issue 5, p 565).
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TREATMENT OF INTERMITTENT CLAUDICATION
B 4.1




The overriding issue in the management of patients
presenting with IC is that they are at significant risk of
developing severe and often fatal cardiovascular com-
plications; thus, their most serious problem is not the
limitation of walking, even though that may be their
only symptom. Patients with IC are at 2 to 4 times
greater risk of dying from the complications of gener-
alised atherosclerosis than similar people without
